Lexeo Therapeutics reports positive interim data and financial results for Q1 2025.

From GlobeNewswire: 2025-05-12 07:00:00

Lexeo Therapeutics announced positive interim data for LX2006 in Friedreich ataxia (FA) cardiomyopathy, with frataxin expression and LVMI improvement exceeding targets. A registrational study for LX2006 is expected to begin by early 2026. Phase 1/2 clinical trial of LX2020 is enrolling patients in Cohort 3, with an update expected in the second half of 2025.

The company redeployed $20 million to focus on clinical-stage programs, with cash, cash equivalents, and investments of $106.9 million expected to provide operational runway into 2027. Lexeo provided business updates and reported first quarter 2025 financial results, highlighting progress in their genetic medicine treatments for cardiovascular diseases.

Efficacy data for LX2006 showed significant improvements in cardiac biomarkers and functional measures, with a mean reduction in LVMI of 25% exceeding the FDA target. Increases in cardiac frataxin expression were observed in all participants. LX2020 also showed positive interim data, with the company redeploying capital towards their lead cardiac programs.

As of March 31, 2025, Lexeo had $106.9 million in cash, cash equivalents, and investments, expected to fund operations into 2027. Research and Development expenses were $17.2 million, while General and Administrative expenses were $16.6 million for the same period. The company reported a net loss of $32.7 million for the first quarter of 2025.

Lexeo Therapeutics is a genetic medicine company focused on reshaping heart health through innovative treatments for cardiovascular diseases. The company’s lead programs, LX2006 for FA cardiomyopathy and LX2020 for PKP2 arrhythmogenic cardiomyopathy, aim to address genetic causes of these conditions with high unmet medical needs.



Read more at GlobeNewswire:: Lexeo Therapeutics Reports First Quarter 2025 Financial